- Home
- ACB vs CRVS Comparison
ACB vs CRVS Comparison
Compare ACB & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- CRVS
- Stock Information
- Founded
- ACB 2013
- CRVS 2014
- Country
- ACB Canada
- CRVS United States
- Employees
- ACB N/A
- CRVS N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- CRVS Health Care
- Exchange
- ACB Nasdaq
- CRVS Nasdaq
- Market Cap
- ACB 256.5M
- CRVS 305.4M
- IPO Year
- ACB N/A
- CRVS 2016
- Fundamental
- Price
- ACB $5.40
- CRVS $4.85
- Analyst Decision
- ACB
- CRVS Strong Buy
- Analyst Count
- ACB 0
- CRVS 4
- Target Price
- ACB N/A
- CRVS $15.00
- AVG Volume (30 Days)
- ACB 1.7M
- CRVS 451.5K
- Earning Date
- ACB 08-06-2025
- CRVS 08-07-2025
- Dividend Yield
- ACB N/A
- CRVS N/A
- EPS Growth
- ACB N/A
- CRVS N/A
- EPS
- ACB N/A
- CRVS N/A
- Revenue
- ACB $262,403,032.00
- CRVS N/A
- Revenue This Year
- ACB $11.13
- CRVS N/A
- Revenue Next Year
- ACB $5.39
- CRVS N/A
- P/E Ratio
- ACB N/A
- CRVS N/A
- Revenue Growth
- ACB 28.58
- CRVS N/A
- 52 Week Low
- ACB $3.42
- CRVS $2.54
- 52 Week High
- ACB $7.20
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ACB 63.62
- CRVS 62.34
- Support Level
- ACB $4.14
- CRVS $4.05
- Resistance Level
- ACB $5.59
- CRVS $5.05
- Average True Range (ATR)
- ACB 0.28
- CRVS 0.25
- MACD
- ACB 0.12
- CRVS 0.04
- Stochastic Oscillator
- ACB 87.93
- CRVS 81.65
About ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).